AOR
Archives of Ophthalmological Research

The Archives of Ophthalmological Research aims to publish issues related to publish articles of the highest scientific and clinical value at an international level, and accepts articles on these topics. The target audience of the journal included specialists and physicians working in ophthalmology, and other health professionals interested in these fields.

eISSN: 3023-6479
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Evaluation of the long-term efficacy of intravitreal bevacizumab in retinopathy of prematurity
Abstract
Aims: To evaluate post-treatment retinal vascularization in infants treated with intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP).
Methods: This study retrospectively evaluated data from cases treated for Type 1 ROP and AP-ROP between 2021 and 2024, followed by an examination of the birth weeks, birth weights, post-gestational treatment weeks, retinal vascularization periods, recurrence, and additional treatment needs of these cases.
Results: A total of 58 eyes of 30 infants were included in the study. Intravitreal bevacizumab (0.625 mg/0.025 ml) was injected into 58 eyes of 30 cases. The mean birth weight of the cases was 1178±509 grams (500-2790), and their mean gestational age was 28.2±2.7 weeks (23-34). The mean post-gestational week of IVB treatment was 36.6±2.1 (32-39), with a mean follow-up period of 29.5±4.3 weeks (21-37) after treatment. Following treatment, ROP symptoms were observed to largely regress in all cases, with the plus disease also regressing. Additional laser photocoagulation was performed in four eyes of two cases. The mean week for complete retinal vascularization was 61.9±3.5 (55-67).
Conclusion: High rates of regression can be achieved with intravitreal bevacizumab monotherapy in Type 1 ROP and AP-ROP cases. Furthermore, complete retinal vascularization can be attained during long-term follow-up.

Keywords : Retinopathy of prematurity, intravitreal bevacizumab, retinal vascularization

Download Article


1. Miller MM, Revenis ME, Lai MM, et al. Risk and clinical course of retinopathy of prematurity in 78 infants of gestational age 22-25 weeks. J AAPOS. 2014;18(3):266-270.
2. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77-82.
3. Günay M, Topçuoğlu S, Çelik G, Gürsoy T. Prematüre retinopatisi: sıklık azalıyor mu? Zeynep Kamil Tip Bult. 2013;44(4):214-220.
4. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684-1694.
5. International Committee for the Classification of Retinopathy of Prematurity. The International classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991-999.
6. Drenser KA, Trese MT, Capone A Jr. Aggressive posterior retinopathy of prematurity. Retina. 2010;30(4 Suppl):S37-S40.
7. Good WV. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248.
8. Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155(6):1119-1124.
9. Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015; 122(5):1008-1015.
10. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.
11. Fierson WM, Saunders RA, Good W, et al; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189-195.
12. Koç E, Baş AY, Özdek Ş, et al. Türkiye prematüre retinopatisi rehberi 2016. Available from http://www.neonatology.org.tr/wp-content/uploads/ 2016/12/premature_retinopatisi_rehberi.pdf
13. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of pre­maturity: results of the early treatment for retinopathy of pre­maturity randomized trial. Arch Ophthalmol. 2003;121(12):1684-1694.
14. Quinn GE, Dobson V, Barr CC, et al. Visual acuity of eyes af­ter vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. Ophthalmology. 1996;103(4):595-600.
15. Repka MX, Tung B, Good WV, et al. Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study (ETROP). Arch Ophthalmol. 2006;124(1):24-30.
16. Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS. 2010;14(1):2-3.
17. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.
18. Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155(6):1119-1124.
19. Alyamac SE, Comez A, Koçluk Y, et al. The process of retinal vascularization after anti-vegf treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016;236(3):139-147.
20. Spandau U, Tomic, Ewald U, et al. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol Acta Ophthalmol. 2013;91(2):170-175.
21. Yetik H, Gunay M, Sirop S, et al. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity-27 month follow-up results from Turkiye. Graefes Arch Clin Exp Ophthalmol. 2015;253(10):1677-1683.
22. Martínez-Castellanos MA, González-H León A, Romo-Aguas JC, Gonzalez-Gonzalez LA. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefes Arch Clin Exp Ophthalmol. 2020;258(4):767-772. doi:10.1007/s00417-020-04605-y
23. Nicoara SD, ?tefanut AC, Nascutzy C, et al. Regression rate following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit. 2016;22:1192-1209.
24. Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135(6):654-656.
25. Çömez A, Karaküçük Y, Özmen MC, Çelemler P, Saygılı O. The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and type 1 retinopathy of prematurity. Eye (Lond). 2021;35(12):3302-3310.
Article available in :
Volume 2, Issue 1, 2025
Page : 5-8
https://doi.org/10.51271/AOR-0023
Article Information
Received : 03 Kas 2024
Accepted : 28 Kas 2024
Published : 07 Oca 2025
Corresponding Author :

Yasemin Harbalıoğlu: Department of Ophthalmology, Samsun Training and ResearchHospital, Samsun, Turkiye

[email protected]
Citation : Harbalıoğlu Y. Evaluation of the long-term efficacy of intravitreal bevacizumab in retinopathy of prematurity. Arch Ophthalmol Res. 2025;2(1):5-8.

Read: 27
Cited: 0
Download : 8
_Footer